Which has better earnings & valuation, NBTX or AQST?

Nanobiotix has higher earnings, but lower revenue than Aquestive Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanobiotix $36.87M 49.05 -$27.11M N/A N/A Aquestive Therapeutics $44.54M 11.10 -$83.78M -$0.61 N/A

Is NBTX or AQST more profitable?

Nanobiotix has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%. Company Net Margins Return on Equity Return on Assets Nanobiotix N/A N/A N/A Aquestive Therapeutics -137.08% N/A -49.33%

Does the media prefer NBTX or AQST?

In the previous week, Nanobiotix had 3 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 4 mentions for Nanobiotix and 1 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 1.34 beat Nanobiotix's score of 0.85 indicating that Aquestive Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanobiotix 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aquestive Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AQST or NTLA?

In the previous week, Intellia Therapeutics had 1 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 2 mentions for Intellia Therapeutics and 1 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 1.34 beat Intellia Therapeutics' score of 0.89 indicating that Aquestive Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aquestive Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intellia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AQST or SION?

In the previous week, Sionna Therapeutics had 3 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 4 mentions for Sionna Therapeutics and 1 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 1.34 beat Sionna Therapeutics' score of 0.87 indicating that Aquestive Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aquestive Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sionna Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SRPT or AQST?

In the previous week, Sarepta Therapeutics had 1 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 2 mentions for Sarepta Therapeutics and 1 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 1.34 beat Sarepta Therapeutics' score of 0.67 indicating that Aquestive Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aquestive Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is AQST or LKFT more profitable?

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%. Company Net Margins Return on Equity Return on Assets Aquestive Therapeutics -137.08% N/A -49.33% Lakefront Biotherapeutics American Depositary Shares N/A N/A N/A

Aquestive Therapeutics (AQST) Competitors

$3.94 -0.18 (-4.37%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$4.04 +0.10 (+2.54%)

As of 07/20/2026 07:54 PM Eastern

Compare

AQST vs. NBTX, NTLA, SION, SRPT, and LKFT

Should you buy Aquestive Therapeutics stock or one of its competitors? MarketBeat compares Aquestive Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aquestive Therapeutics include Nanobiotix (NBTX), Intellia Therapeutics (NTLA), Sionna Therapeutics (SION), Sarepta Therapeutics (SRPT), and Lakefront Biotherapeutics American Depositary Shares (LKFT). These companies are all part of the "pharmaceutical products" industry.

How does Aquestive Therapeutics compare to Nanobiotix?

Nanobiotix (NASDAQ:NBTX) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

Nanobiotix has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market.

Nanobiotix has higher earnings, but lower revenue than Aquestive Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$36.87M	49.05	-$27.11M	N/A	N/A
Aquestive Therapeutics	$44.54M	11.10	-$83.78M	-$0.61	N/A

38.8% of Nanobiotix shares are held by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are held by institutional investors. 3.5% of Nanobiotix shares are held by insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Nanobiotix has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%.

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
Aquestive Therapeutics	-137.08%	N/A	-49.33%

In the previous week, Nanobiotix had 3 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 4 mentions for Nanobiotix and 1 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 1.34 beat Nanobiotix's score of 0.85 indicating that Aquestive Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanobiotix	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aquestive Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nanobiotix presently has a consensus price target of $37.33, suggesting a potential upside of 4.49%. Aquestive Therapeutics has a consensus price target of $8.50, suggesting a potential upside of 115.74%. Given Aquestive Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aquestive Therapeutics is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Aquestive Therapeutics beats Nanobiotix on 7 of the 13 factors compared between the two stocks.

How does Aquestive Therapeutics compare to Intellia Therapeutics?

Aquestive Therapeutics (NASDAQ:AQST) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

Aquestive Therapeutics has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

Aquestive Therapeutics has a net margin of -137.08% compared to Intellia Therapeutics' net margin of -597.04%. Aquestive Therapeutics' return on equity of 0.00% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-137.08%	N/A	-49.33%
Intellia Therapeutics	-597.04%	-57.47%	-46.24%

In the previous week, Intellia Therapeutics had 1 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 2 mentions for Intellia Therapeutics and 1 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 1.34 beat Intellia Therapeutics' score of 0.89 indicating that Aquestive Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aquestive Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Intellia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

32.5% of Aquestive Therapeutics shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 6.8% of Aquestive Therapeutics shares are held by company insiders. Comparatively, 3.5% of Intellia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Aquestive Therapeutics has higher earnings, but lower revenue than Intellia Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54M	11.10	-$83.78M	-$0.61	N/A
Intellia Therapeutics	$67.67M	22.55	-$412.69M	-$3.54	N/A

Aquestive Therapeutics presently has a consensus price target of $8.50, suggesting a potential upside of 115.74%. Intellia Therapeutics has a consensus price target of $20.19, suggesting a potential upside of 84.87%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aquestive Therapeutics is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Intellia Therapeutics	4 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.30

Summary

Aquestive Therapeutics beats Intellia Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Aquestive Therapeutics compare to Sionna Therapeutics?

Aquestive Therapeutics (NASDAQ:AQST) and Sionna Therapeutics (NASDAQ:SION) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

32.5% of Aquestive Therapeutics shares are held by institutional investors. 6.8% of Aquestive Therapeutics shares are held by insiders. Comparatively, 5.1% of Sionna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Aquestive Therapeutics presently has a consensus target price of $8.50, suggesting a potential upside of 115.74%. Sionna Therapeutics has a consensus target price of $53.22, suggesting a potential upside of 16.49%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aquestive Therapeutics is more favorable than Sionna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Sionna Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.85

Sionna Therapeutics has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%. Aquestive Therapeutics' return on equity of 0.00% beat Sionna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-137.08%	N/A	-49.33%
Sionna Therapeutics	N/A	-27.31%	-25.88%

In the previous week, Sionna Therapeutics had 3 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 4 mentions for Sionna Therapeutics and 1 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 1.34 beat Sionna Therapeutics' score of 0.87 indicating that Aquestive Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aquestive Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sionna Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sionna Therapeutics has lower revenue, but higher earnings than Aquestive Therapeutics. Sionna Therapeutics is trading at a lower price-to-earnings ratio than Aquestive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54M	11.10	-$83.78M	-$0.61	N/A
Sionna Therapeutics	N/A	N/A	-$75.27M	-$1.93	N/A

Aquestive Therapeutics has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 1.33, suggesting that its stock price is 33% more volatile than the broader market.

Summary

Aquestive Therapeutics beats Sionna Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Aquestive Therapeutics compare to Sarepta Therapeutics?

Sarepta Therapeutics (NASDAQ:SRPT) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

Sarepta Therapeutics presently has a consensus price target of $23.90, indicating a potential upside of 42.04%. Aquestive Therapeutics has a consensus price target of $8.50, indicating a potential upside of 115.74%. Given Aquestive Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aquestive Therapeutics is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	7 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.08
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Sarepta Therapeutics had 1 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 2 mentions for Sarepta Therapeutics and 1 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 1.34 beat Sarepta Therapeutics' score of 0.67 indicating that Aquestive Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aquestive Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aquestive Therapeutics has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Aquestive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.81	-$713.41M	-$0.96	N/A
Aquestive Therapeutics	$44.54M	11.10	-$83.78M	-$0.61	N/A

Sarepta Therapeutics has a net margin of -2.94% compared to Aquestive Therapeutics' net margin of -137.08%. Sarepta Therapeutics' return on equity of 7.56% beat Aquestive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-2.94%	7.56%	2.94%
Aquestive Therapeutics	-137.08%	N/A	-49.33%

Sarepta Therapeutics has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market.

86.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are held by institutional investors. 6.9% of Sarepta Therapeutics shares are held by insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Aquestive Therapeutics beats Sarepta Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Aquestive Therapeutics compare to Lakefront Biotherapeutics American Depositary Shares?

Aquestive Therapeutics (NASDAQ:AQST) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Aquestive Therapeutics. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Aquestive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54M	11.10	-$83.78M	-$0.61	N/A
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.52	$363.05M	-$1.41	N/A

Aquestive Therapeutics has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market.

In the previous week, Lakefront Biotherapeutics American Depositary Shares had 3 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 4 mentions for Lakefront Biotherapeutics American Depositary Shares and 1 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 1.34 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.56 indicating that Aquestive Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aquestive Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lakefront Biotherapeutics American Depositary Shares	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aquestive Therapeutics presently has a consensus target price of $8.50, suggesting a potential upside of 115.74%. Lakefront Biotherapeutics American Depositary Shares has a consensus target price of $34.33, suggesting a potential upside of 18.31%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aquestive Therapeutics is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Lakefront Biotherapeutics American Depositary Shares	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.11

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-137.08%	N/A	-49.33%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

32.5% of Aquestive Therapeutics shares are owned by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 6.8% of Aquestive Therapeutics shares are owned by company insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Aquestive Therapeutics beats Lakefront Biotherapeutics American Depositary Shares on 10 of the 16 factors compared between the two stocks.

Get Aquestive Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AQST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AQST vs. The Competition

Export

Metric	Aquestive Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$516.92M	$3.07B	$6.89B	$12.28B
Dividend Yield	N/A	2.05%	2.67%	9.39%
P/E Ratio	-6.46	20.20	27.07	23.94
Price / Sales	11.10	340.68	515.91	90.33
Price / Cash	N/A	27.11	26.68	47.25
Price / Book	-14.07	4.20	10.43	6.14
Net Income	-$83.78M	$65.94M	$3.60B	$331.74M
7 Day Performance	-2.48%	-3.05%	-1.20%	-1.82%
1 Month Performance	-16.08%	-1.30%	1.12%	-1.45%
1 Year Performance	-6.86%	15.22%	23.66%	16.32%

Aquestive Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AQST Aquestive Therapeutics	2.983 of 5 stars	$3.94 -4.4%	$8.50 +115.7%	-6.2%	$516.92M	$44.54M	N/A	160	Positive News
NBTX Nanobiotix	2.2958 of 5 stars	$40.14 +3.1%	$37.33 -7.0%	+579.3%	$2.03B	$36.87M	N/A	100	News Coverage Gap Up
NTLA Intellia Therapeutics	3.2957 of 5 stars	$14.47 -6.3%	$20.67 +42.9%	-9.5%	$2.03B	$67.67M	N/A	600
SION Sionna Therapeutics	1.9378 of 5 stars	$44.71 -0.5%	$53.22 +19.0%	+172.9%	$2.02B	N/A	N/A	35	News Coverage
SRPT Sarepta Therapeutics	2.663 of 5 stars	$19.01 -7.4%	$25.09 +32.0%	+19.6%	$2.01B	$2.20B	N/A	1,372

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AQST) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aquestive Therapeutics (AQST) Competitors

AQST vs. NBTX, NTLA, SION, SRPT, and LKFT

How does Aquestive Therapeutics compare to Nanobiotix?

Summary

How does Aquestive Therapeutics compare to Intellia Therapeutics?

Summary

How does Aquestive Therapeutics compare to Sionna Therapeutics?

Summary

How does Aquestive Therapeutics compare to Sarepta Therapeutics?

Summary

How does Aquestive Therapeutics compare to Lakefront Biotherapeutics American Depositary Shares?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQST vs. The Competition

Aquestive Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aquestive Therapeutics (AQST) Competitors

AQST vs. NBTX, NTLA, SION, SRPT, and LKFT

How does Aquestive Therapeutics compare to Nanobiotix?

Which has more volatility & risk, NBTX or AQST?

Which has better earnings & valuation, NBTX or AQST?

Do institutionals and insiders hold more shares of NBTX or AQST?

Is NBTX or AQST more profitable?

Does the media prefer NBTX or AQST?

Do analysts prefer NBTX or AQST?

Summary

How does Aquestive Therapeutics compare to Intellia Therapeutics?

Which has more volatility and risk, AQST or NTLA?

Is AQST or NTLA more profitable?

Does the media refer more to AQST or NTLA?

Do institutionals & insiders hold more shares of AQST or NTLA?

Which has stronger valuation & earnings, AQST or NTLA?

Do analysts prefer AQST or NTLA?

Summary

How does Aquestive Therapeutics compare to Sionna Therapeutics?

Do institutionals and insiders have more ownership in AQST or SION?

Do analysts recommend AQST or SION?

Is AQST or SION more profitable?

Does the media refer more to AQST or SION?

Which has stronger earnings & valuation, AQST or SION?

Which has more volatility and risk, AQST or SION?

Summary

How does Aquestive Therapeutics compare to Sarepta Therapeutics?

Do analysts rate SRPT or AQST?

Does the media prefer SRPT or AQST?

Which has better earnings & valuation, SRPT or AQST?

Is SRPT or AQST more profitable?

Which has more volatility & risk, SRPT or AQST?

Do insiders and institutionals believe in SRPT or AQST?

Summary

How does Aquestive Therapeutics compare to Lakefront Biotherapeutics American Depositary Shares?

Which has higher earnings & valuation, AQST or LKFT?

Which has more volatility & risk, AQST or LKFT?

Does the media refer more to AQST or LKFT?

Do analysts rate AQST or LKFT?

Is AQST or LKFT more profitable?

Do insiders and institutionals have more ownership in AQST or LKFT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQST vs. The Competition

Aquestive Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools